Cardiovascular Risk Factors: Interactive Effects of Lipids, Coagulation and Fibrinolysis

References

• Dawber T R, Kannel W B, Revotskie N, Kogan A. The epidemiology of coronary heart disease. The Framingham enquery. Proc Roy Soc Med 1962; 55: 265–71
   PubMedGoogle Scholar
• Westlund K, Nicolaysen R. Serum cholesterol and risk of mortality and morbidity. Scand J Clin Lab Invest 1966; 18(suppl 87)1–19
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L, Wedel H, Tibblin G. Multivariate analysis of risk factors for coronary heart disease. Circulation 1973; 48: 950–8
   PubMed Web of Science ®Google Scholar
• Gordon J, Probstfield J L, Garrison R J, Neaton J D, Castelli W P, Knoke J D, Jacobs D R, Bangdiwala S, Tyrole H A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8–15
   PubMed Web of Science ®Google Scholar
• Austin M A. Plasma triglyceride and coronary heart disease. Arteriosclerosis and Thromb 1991; 11: 2–14
   PubMed Web of Science ®Google Scholar
• Meade T W, Mellows S, Brozovic M, Miller G J, Chakrabarti R R, North W RS, Haines A P, Stirling Y, Imeson J D, Thompson S G. Haemostatic function and ischaemic heart disease. Principle results of the Northwhick Park Heart Study. Lancet 1986; ii: 533–7
   Google Scholar
• Hamsten A, DeFaire U, Walldius G. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3–9
   Google Scholar
• Skartlien A H, Beckmann S L, Holme I, Hjermann I, Prydz H. Effect of alteration in triglyceride levels on Factor VII phospholipid complexes in plasma. Arteriosclerosis 1989; 9: 798–801
   PubMedGoogle Scholar
• Berg K. A new serumtype system in man - the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369–82
   PubMedGoogle Scholar
• Kostner G M, Krempler F. Lipoprotein (a). Curr Opin Lipidol 1992; 3: 279–84
   Google Scholar
• Hjermann I. The metabolic cardiovascular syndrome: Syndrome X, Reavens syndrome, insulin resistance syndrome, atherothrombogenic syndrome. J Cardiovasc Pharmacol 1992; 20(suppl 8)S5–S10
   Google Scholar
• Müller C. Angina pectoris in hereditary xanthomatosis. Arch Intern Med 1939; 64: 675–700
   Google Scholar
• Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction: A controlled trial. Acta Med Scand 1966, suppl 466
   Google Scholar
• Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981; ii: 1303–10
   Google Scholar
• Bjartveit K, Foss O P, Gjervig T, Lund-Larsen P G. The cardiovascular disease study in Norwegian counties. Background and organization. Acta Med Scand 1979, suppl 634: l–70
   Google Scholar
• Bjartveit K, Foss O P, Gjervig T. The cardiovascular disease study in Norwegian counties. Results from first screening. Acta Med Scand 1983, suppl 675: 1–184
   Google Scholar
• Tretli S, Bjartveit K, Foss O P, Haider T, Lund-Larsen P G. Intervention of cardiovascular risk factors in Finnmark county: Changes after a period of three years. Scand J Soc Med 1985; 13: 1–13
   PubMedGoogle Scholar
• Bjartveit K, Stensvold I, Lund-Larsen P G, Gjervig T, Krüger Ø, Urdal P. Cardiovascular disease prevention programmes in Norwegian counties. Background and implementation. Status of risk patterns in persons aged 40–42 in 14 counties, 1986–90. Tidskr Nor Laegeforen 1991; 111: 2063–72
   PubMedGoogle Scholar
• Bjartveit K, Stensvold I, Lund-Larsen P G, Graff-Iversen S, Urdal P. Cardiovascular disease prevention programmes in Norwegian counties. Trends in risk pattern among persons aged 40–42 in four counties, 1985–90. Tidskr Nor Lægeforen 1991; 111: 2072–6
   PubMedGoogle Scholar
• Johansson L, Bjørneboe G E. The Norwegian diet is improving. Tidsskr Nor Lægeforen 1991; 111: 3199–201
   PubMedGoogle Scholar
• Bennett S T, Eckfeldt J H, Belcher J D, Connelly D P. Certification of cholesterol measurements by the National Reference Method Laboratory Network with routine clinical specimens: Effect of network laboratory bias and imprecision. Clin Chem 1992; 38: 651
   PubMed Web of Science ®Google Scholar
• Tverdal A, Foss O P, Leren P, Holme I, Lund-Larsen P G, Bjartveit K. Serum triglycerides as an independent risk factor for death from coronary heart disease in middle-aged Norwegian men. Am J Epidemiol 1989; 129: 458–65
   PubMed Web of Science ®Google Scholar
• Stensvold I, Urdal P, Thurmer H, Tverdal A, Lund-Larsen P G, Foss O P. High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women. Eur Heart J 1992; 13: 115–63
   PubMed Web of Science ®Google Scholar
• Foss O P, Lund-Larsen P G. Serum thiocyanate and smoking: Interpretation of serum thiocyanate levels observed in a large health study. Scand J Clin Lab Invest 1986; 46: 245–51
   PubMed Web of Science ®Google Scholar
• Ernst E. Plasma fibrinogen - an independent cardiovascular risk factor. J Int Med 1990; 227: 365–72
   PubMed Web of Science ®Google Scholar
• Høstmark A T, Bjerkedal T, Kierulf P, Flaten H, Ulshagen K. Fish oil and plasma fibrinogen. Br Med J 1988; 297: 180–1
   PubMed Web of Science ®Google Scholar
• Humphries S E, Cook M, Stirling Y, Meade T W. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; i: 1452–4
   Google Scholar
• Horge H W, Personal communication
   Google Scholar
• Helgeland A, Hjermann I, Leren P, Enger S C, Holme I. High-density lipoprotein cholesterol and hypertensive drugs. The Oslo Study. Br Med J 1978; ii: 403
   Google Scholar
• Leren P, Foss O P, Helgeland A, Hjermann I, Holme I, Lund-Larsen P G. Effect of propanolol and prazosin on blood lipids. The Oslo Study. Lancet 1980; ii: 4–6
   Google Scholar
• Talseth T, Westlie L, Daae L. Doxazosin and atenolol as monotherapy in mild and moderate hypertension. A randomized, parallel study with a three-year follow-up. Am Heart J 1991; 121: 280–5
   PubMed Web of Science ®Google Scholar
• Westheim A, Daae L, Kierulf P, Brusletto B, Holme I, Syvertsen J O. Selective ar inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects. J Hypertens 1990; 8(suppl 5)S41–S46
   Google Scholar
• Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147–52
   PubMed Web of Science ®Google Scholar
• Entsland J, Seljenot I, Arnesen H, Abdelnoor M, Kierulf P. Long-term influence of omega-3 fatty acids on blood coagulation and fibrinolysis. Oslo, Norway 1992, Abstr. no. 28, Omega-3 fatty acids. Metabolism & Biological effects Sept. 15–19
   Google Scholar
• Eritsland J, Seljenot I, Arnesen H, Westvik A B, Kierulf P. Plasma from patients supplemented with omega-3 fatty acids does not modify the procoagulant activity of cultured monocytes. Abstr. no. 142, Omega-3 fatty acids. Metabolism & Biological effects. Oslo, Norway 1992, Sept. 15–19
   Google Scholar
• Steinberg D, Parthasarathy S, Carew T E, Witztum J. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Eng J Med 1989; 320: 915–24
   PubMed Web of Science ®Google Scholar
• Kierulf P, Andersen A BW. Lipopolysaccharide-instructed, cryopreserved, human monocytes sequentially convert plasma fibrinogen to fibrin and lyse the fibrin formed. Pathobiology 1991; 59: 197–9
   PubMed Web of Science ®Google Scholar
• Gordon D J, Rifkind B M. High-density lipoprotein - the clinical implications of recent studies. N Eng J Med 1989; 321: 1311–5
   PubMed Web of Science ®Google Scholar
• Eggesbø J B, Hjermann I, Høstmark A, Joø G B, Kierulf P. Endotoxin induced monocyte procoagulant activity, fibrinopeptide-A, and PAI-1 levels in persons with high- and low levels of serum HDL-lipoproteins. Thromb Res, (in press)
   Google Scholar
• Eggesbø J B, Hjermann I, Hostmark A, Joo G B, Lund P K, Kierulf P. LPS-induced monocyte (MO) procoagulant activity (PCA) and 1L-6 release in an “ex vivo” whole blood model from persons with high or low S-HDL-lipoprotein levels. Abstr. no. 325, 2nd Conf. Int. Endotoxin Soc. Austria. Aug. 17–20, 1992
   Google Scholar